Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,632.19
(
0.00%
)
US TECH 100
24,014.00
(
1.12%
)
Dow Jones
46,558.47
(
0.00%
)
Brent Oil
99.41
(
-1.80%
)
Bitcoin
73,818.07
(
1.39%
)
News Focus
News Focus
Post# of 372269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

nlightn

Send PM Follow Ignore
Followers 137
Posts 41656
Boards Moderated 7
Alias Born 01/05/2004

nlightn

Re: nlightn post# 240193

Wednesday, 04/15/2015 9:59:27 AM

Wednesday, April 15, 2015 9:59:27 AM

Post# of 372269
$AZN,...AstraZeneca's tremelimumab an Orphan Drug for mesothelioma

The FDA designates AstraZeneca's (AZN +1.4%) anti-CTLA-4 monoclonal antibody, tremelimumab, an Orphan Drug for the treatment of malignant mesothelioma, an aggressive cancer affecting the lining of the lungs and abdomen that is associated with asbestos exposure.

Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

invest at your own risk, based on your own due diligence, at your own risk tolerance

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now